According to a market analysis published by SNS Insider and distributed through GlobeNewswire, the global lung cancer liquid biopsy market—valued at USD 1,142.60 million in 2025—is projected to reach USD 3,947.60 million by 2035, a compound annual growth rate of 13.2% sustained by widening regulatory approval for blood-based genomic profiling, expanded reimbursement coverage, and the deepening integration of liquid biopsy into pharmaceutical protocols for targeted and immune-based therapies. For molecular pathology laboratories and clinical oncology programs, the convergence of FDA companion diagnostic decisions, validated early-detection assays, and shifting analyte preferences signals a structural reconfiguration in how non-small cell lung cancer and adjacent malignancies will be staged, stratified, and longitudinally monitored.
Market Architecture and Analyte Stratification
The ctDNA segment commanded 61.80% of global share in 2025, a position anchored by its entrenched role in FDA-approved companion diagnostics and its established reimbursement precedent. Exosomes and extracellular vesicles, by contrast, constitute the fastest-growing analyte category, propelled by ongoing evaluation of cell-free RNA and protein cargo as biomarkers of therapy resistance. On the technology axis, NGS-based comprehensive genomic profiling retained 52.70% of market share in 2025, while fragmentomics and methylation analytics—favored for reduced sequencing depth and lower per-sample cost—represent the steepest growth trajectory within the technology segment.
The United States market is projected to expand from approximately USD 441.40 million in 2025 to USD 1,472.10 million by 2035 (CAGR ~12.8%), with Medicare coverage determinations, concentrated test-provider infrastructure, and physician and patient preference for blood-based sampling over repeated tissue biopsy cited as the principal domestic accelerants.
Companion Diagnostic Expansion and Cross-Disease Early Detection
In a parallel regulatory development reported by The ASCO Post, the FDA approved Guardant Health's Guardant360 CDx as a companion diagnostic to identify ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer patients eligible for treatment with imlunestrant plus abemaciclib, a decision coinciding with therapeutic approval grounded in the Phase 3 EMBER-3 trial.
Separately, early-detection research has crossed a measurable threshold in pancreatic ductal adenocarcinoma. A study led by investigators at City of Hope and published in Nature Medicine evaluated PANXEON, an investigational blood-based assay interrogating circulating microRNAs, exosomal microRNAs, and the CA19-9 protein through an artificial intelligence–integrated risk score, across nearly 1,800 patients in the United States, Europe, and Asia. The test identified stage 1 and stage 2 pancreatic cancer with 87% sensitivity, registered a 3% false-positive rate in low-risk cohorts and 16% in high-risk cohorts, and detected high-grade dysplasia—an advanced precancerous condition often described as stage 0 disease—in excess of 64% of cases. Ajay Goel, Ph.D., AGAF, chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope, framed the clinical positioning of the assay accordingly: "Pancreatic cancer remains so deadly largely because we find it after the window for cure has begun to close." The investigators position PANXEON as a triage instrument to identify high-risk patients warranting further imaging evaluation, rather than a replacement for established diagnostic modalities.
Forward Trajectory for Molecular Pathology Operations
Three vectors warrant structured monitoring over the coming quarters. First, the cadence of Medicare local coverage determinations for NGS-based liquid biopsy panels in lung cancer, which will determine the speed at which community oncology workflows absorb comprehensive genomic profiling into routine practice. Second, the clinical adoption curve for Guardant360 CDx in ESR1-mutated breast cancer as EMBER-3-based therapeutic stratification moves downstream into community infusion settings. Third, the prospective validation trajectory for multi-analyte early-detection assays such as PANXEON as they transition from investigational status toward regulatory engagement, with direct bearing on laboratory test menu design, sequencing capacity planning, and the operational integration of AI-driven interpretation pipelines across hospital and reference laboratory networks.